Proficio Capital Partners LLC reduced its stake in shares of SPDR S&P Biotech ETF (NYSEARCA:XBI – Free Report) by 84.5% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 5,643 shares of the exchange traded fund’s stock after selling 30,792 shares during the quarter. Proficio Capital Partners LLC’s holdings in SPDR S&P Biotech ETF were worth $558,000 as of its most recent SEC filing.
Other large investors also recently modified their holdings of the company. Fifth Third Bancorp grew its holdings in shares of SPDR S&P Biotech ETF by 3.4% during the 2nd quarter. Fifth Third Bancorp now owns 118,303 shares of the exchange traded fund’s stock worth $10,968,000 after purchasing an additional 3,922 shares in the last quarter. Avantax Advisory Services Inc. boosted its stake in SPDR S&P Biotech ETF by 17.2% in the first quarter. Avantax Advisory Services Inc. now owns 9,619 shares of the exchange traded fund’s stock valued at $913,000 after buying an additional 1,415 shares in the last quarter. PFG Investments LLC boosted its stake in SPDR S&P Biotech ETF by 9.2% in the second quarter. PFG Investments LLC now owns 24,844 shares of the exchange traded fund’s stock valued at $2,303,000 after buying an additional 2,097 shares in the last quarter. IFG Advisory LLC acquired a new stake in SPDR S&P Biotech ETF in the second quarter valued at about $241,000. Finally, Atria Wealth Solutions Inc. boosted its stake in SPDR S&P Biotech ETF by 56.1% in the second quarter. Atria Wealth Solutions Inc. now owns 16,597 shares of the exchange traded fund’s stock valued at $1,539,000 after buying an additional 5,962 shares in the last quarter.
SPDR S&P Biotech ETF Stock Up 1.1 %
NYSEARCA:XBI opened at $104.18 on Monday. The stock’s 50-day simple moving average is $98.96 and its 200 day simple moving average is $95.68. The firm has a market capitalization of $7.94 billion, a PE ratio of 11.47 and a beta of 1.11. SPDR S&P Biotech ETF has a twelve month low of $64.99 and a twelve month high of $104.22.
About SPDR S&P Biotech ETF
SPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges.
See Also
- Five stocks we like better than SPDR S&P Biotech ETF
- Insider Trades May Not Tell You What You Think
- California Resources Stock Could Be a Huge Long-Term Winner
- Which Wall Street Analysts are the Most Accurate?
- Observability Wars: Datadog and Dynatrace Vie for Data Dominance
- Stock Splits, Do They Really Impact Investors?
- Airbnb Stock Attracts Attention With Strong Cash Flow Strategy
Want to see what other hedge funds are holding XBI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for SPDR S&P Biotech ETF (NYSEARCA:XBI – Free Report).
Receive News & Ratings for SPDR S&P Biotech ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SPDR S&P Biotech ETF and related companies with MarketBeat.com's FREE daily email newsletter.